The global market fortherapeutic monoclonal antibodies (mAbs) was estimated at $44.6 billion in 2011. With the rollout of at least eight new therapeutic mAb products, the global mAb market is expected to rise at a compound annual growth rate (CAGR) of 5.3% to nearly $58 billion in 2016.
Learn about the rapidly growing market for therapeutic mAb disease-modifying products and forecasts for sales of the mAb market by individual antibody, by therapeutic antibody target, and by major disease applications from 2011 through 2016. Companies that lead the biotechnology and pharmaceutical industry in the research and development of antibody drugs are presented as well...
Use this report to:
- Quantify and qualify the rapidly growing market for therapeutic mAb drugs
- Learn about the strategies employed by biopharmaceutical firms to develop and market products in this explosive market sector
- Identify new directions in antibody research, the types of antibodies used as therapeutics, the challenges in antibody production, and other approaches - in particular transgenic sources - of antibody production
- Gain an overview of more than 60 mAb drugs, including those currently marketed and those in late-stage development.
To provide further information about this report we offer a Complimentary Introduction, available from our Website. To download, simply click here, go to the Table of Contents tab, add the complimentary introduction to your cart, and confirm your order.
GLOBAL SALES OF THERAPEUTIC MONOCLONAL ANTIBODIES, 2009-2016
Source - BCC Research